- Revenue from operations at 6,528 crore, up 18% over last year.
- Research & Development (R&D) investments Rs. 479.9 crore (7.4% of revenues).
- EBITDA grows 30 pc to 2,125 crore
NE BUSINESS BUREAU
AHMEDABAD, MAY 21
City-based Zydus Lifesciences Limited on Tuesday reported an 18% year-on-year (YoY) rise in net profit to Rs 1,390.5 crore, (adjusted for exceptional item) for the quarter ended March 31, 2025, driven by robust growth across its US formulations, India branded generics, and consumer wellness businesses.
Consolidated revenue from operations rose 18% YoY to Rs 6,528 crore, while EBITDA surged 30% to Rs 2126 crore, with margins expanding 310 basis points to 32.6%.
For the full fiscal year, revenue climbed 19% to Rs 23,242 crore, and net profit (adjusted for exceptional items) increased 23% to Rs 4745 crore. The company ended the year with a net cash position of Rs 4884 crore, up from Rs 856 crore a year earlier.
“We are happy to conclude FY2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth. We look forward to continued execution success and deepening strategic partnerships to drive long term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering,” said Sharvil Patel, managing director of Zydus Lifesciences.
US formulations revenue rose 24% YoY to Rs 3,131 crore in Q4, driven by volume expansion and five new product launches. The business contributed 50% of consolidated quarterly revenue.
India formulations grew 11% YoY, outperforming the Indian Pharmaceutical Market (IPM), with chronic therapies now comprising 43% of the portfolio.
Consumer wellness sales rose 17% YoY, supported by 13% volume growth and strong performance in personal care and nutrition segments, including contributions from the Naturell acquisition.
International markets revenue grew 12% YoY to Rs 555 crore, led by demand across geographies.
APIs and Alliances declined 10% and 23% YoY respectively.
Zydus invested Rs 1856 crore in R&D during FY25 (8% of revenue), advancing its pipeline in new chemical entities (NCEs), vaccines, and specialty products. The capex spend in FY25 was Rs 1214 crore.
The notable developments include USFDA approval for Phase II(b) trials of Usnoflast for ALS, with Orphan Drug Designation. Progress in Saroglitazar Magnesium trials for PBC and NASH. Initiation of a combination vaccine for shigellosis and typhoid with Gates Foundation support.
The company said it has completed USFDA inspections at multiple facilities with no observations. One site received six observations unrelated to data integrity, which the company is addressing.
Consolidated financial results
| Rs. mn | ǫ4
FY25 |
ǫ4
FY24 |
% Gr.
y-o-y |
ǫ3
FY25 |
% Gr.
q-o-q |
| Revenue from Operations | 65,279 | 55,338 | 18.0% | 52,691 | 23.9% |
| EBITDA | 21,255 | 16,305 | 30.4% | 13,876 | 53.2% |
| EBITDA margin (%) | 32.6% | 29.5% | 26.3% | ||
| PBT1 | 18.916 | 15,470 | 22.3% | 11,841 | 59.8% |
| Net Profit1 | 13,905 | 11,823 | 17.6% | 10,235 | 35.9% |
| Net Profit (Reported) | 11,709 | 11,823 | -1.0% | 10.235 | 14.4% |
| Rs. mn | FY25 | FY24 | % Gr.
y-o-y |
| Revenue from Operations | 2,32,415 | 1,95,474 | 18.9% |
| EBITDA | 70,585 | 53,843 | 31.1% |
| EBITDA margin (%) | 30.4% | 27.5% | |
| PBT1,2 | 62,463 | 48,231 | 29.5% |
| Net Profit1,2 | 47,451 | 38,737 | 22.5% |
| Net Profit (Reported) | 45,255 | 38,595 | 17.3% |
